[1]
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65(2): 87-108.
[2]
Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH,et al.Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66(4): 271-89.
[3]
Ansiaux R, Dewever J, Grégoire V, Feron O, Jordan BF, Gallez B. Decrease in tumor cell oxygen consumption after treatment with vandetanib (ZACTIMA; ZD6474) and its effect on response to radiotherapy. Radiat Res 2009; 172(5): 584-91.
[4]
Zhou QP, Guo JM, Gallo P. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Res 2008; 14(5): 1540-9.
[5]
Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: Chemotherapeutics as antiangiogenics. J Clin Oncol 2001; 19(4): 1195-206.
[6]
Malissen B, P. Bongrand. Early T cell activation: Integrating biochemical, structural, and biophysical cues. Annu Rev Immunol 2015; 33: 539-61.
[7]
Ramos CA, Savoldo B, Dotti G. CD19-CAR trials. Cancer J 2014; 20(2): 112-8.
[8]
Sadelain M. CD19 CAR T Cells. Cell 2017; 171(7): 1471-8.
[9]
Zhang WY, Wang Y, Guo YL, Dai HR, Yang QM, Zhang YJ,et al.Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An early Phase IIa trial report. Signal Transduct Target Ther 2016; 1: 16002-9.
[10]
Lo AS, Xu C, Murakami A, Marasco WA. Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor. Mol Ther Oncolytics 2014; 1: 14003-8.
[11]
Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer Discov 2013; 3(4): 388-98.
[12]
Kakarla S, Gottschalk S. CAR T cells for solid tumors: armed and ready to go? Cancer J 2014; 20(2): 151-5.
[13]
Epstein AL, Hu PS, Pinski JK. CAR T-cell therapy directed to LHR for the treatment of solid tumors. AU2016243124 (2017)
[14]
Li HS. Anti-robo1 CAR-T cell, and preparation and application thereof. WO2017181552 (2017)
[15]
Jiang JT, Lu BF, Chen YA, Chen LJ. CEA.CAR-T (carcinoembryonic antigen.chimeric antigen receptor-T) and preparation method and application thereof. CN107056952 (2017)
[16]
Rehm A, Höpken UE, Bluhm J, Uckert W, Kieback E, Marino S. Chimeric antigen receptor and CAR-T cells that bind BCMA. WO2017211900 (2017)
[17]
Balyasnikova IV, Lesniak MS, Gottschalk SMG. CAR Tcells recognizing cancer-specific IL13Rα2. WO2016123143 (2016)
[18]
Liu WB. Anti-MUC1 CAR-T cell and its preparation method and application. CN107227299 (2017)
[19]
Zeng XZ, Zhang Y. CAR-T cell as well as preparation method and application thereof. CN106047817 (2016)
[20]
Qi W, Yu L, Ou HG. Mesothelin-targeted replication-defective recombinant lentivirus CAR-T transgenic carrier as well as establishment method and application thereof. CN105969805 (2016)
[21]
Qi W, Yu L, Ou HG. CD 30-targeting replication-defective recombinant lentivirus CAR-T transgenic vector as well as construction method and applications thereof. CN105950663 (2016)
[22]
Zhou X. CAR-T cell preparation for treating prostatic cancer and preparation method thereof. CN105640991 (2016)
[23]
Liu WB. Anti AFP (alpha-fetoprotein) CAR-T (chimeric antigen receptor T) cell, preparation method thereof and application of cell. CN107254447 (2017)
[24]
Brogdon J, Gill S, Glass D,et al.Porter. D.L., Ruella, M., Wang, Yq., Wu, Q.L., Zhang, J.Q. Treatment of cancer using a CD123 chimeric antigen receptor. US 20160068601 In: (2016)
[25]
Ebersbach HE, Huber T, Jascur J,et al.Treatment of cancer using a CD33 chimeric antigen receptor. US20160096892 (2016)
[26]
Morgan RA, Rosenberg SA. Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer. US20160200819 (2016)
[27]
Rosenberg SA, Chinnasamy D. Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer. US20130225668 (2013)
[28]
Leong SR, Liang WC, Wu Y, Crocker L, Cheng E, Sampath D,et al.An anti-B7-H4 antibody-drug conjugate for the treatment of breast cancer. Mol Pharm 2015; 12(6): 1717-29.
[29]
Epstein AL, Hu PS. CAR T-cells for the treatment of B7-H4 expressing solid tumors. AU2016243126 (2017).
[30]
Loumagne L, Baudhuin J, Favier B, Montespan F, Carosella ED, Rouas-Freiss N. In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance. Int J Cancer 2014; 135(9): 2107-17.
[31]
Epstein AL, Hu PS. HLA-G as a novel target for CAR T-cell immunotherapy. CA2981166 (2016)
[32]
Pulé M, Anderson J, Thomas S. Chimeric antigen receptor. WO2015132604 (2018)
[33]
Tamada K, Sakoda Y, Ishizaki H. Chimeric antigen receptor. WO2018181207 (2018)
[34]
Bicknell R, Lee S, Mount N, Sharpe M. Chimeric antigen receptor. AU2017232431 (2018)
[35]
Dai HJ, Zhang Z, Li XL, Zhou J, Zhao XD, Xiong B. Specific chimeric antigen receptor targeting NKG2DL and CAR-T cell thereof and use thereof. WO2018165913 (2018)
[36]
Dotti G, Ferrone S. CSGP4-specific chimeric antigen receptor for cancer. US2018251568 (2018)
[37]
Yao YH, Huang JQ, Zhu SG,et al. Construction of chimeric antigen receptor targeting cd20 antigen and activity identification of engineered t cells thereof. WO2018145649 (2018)
[38]
Yang L, Zhang P. Targeted CSF1R chimeric antigen receptor modified NK92MI cell, T cell, and preparation method and application of cells. CN108276495 (2018)
[39]
Wang YS, Wei YQ, Guo FC, Wang W. Chimeric antigen receptor modified lymphocyte capable of expressing CXCR4, and preparation method and applications thereof. CN108277205 (2018)
[40]
Mamonkin M, Brenner MK. CD5 chimeric antigen receptor for adoptive T cell therapy. US2018104308 (2018)
[41]
Muta H, Podack ER. CD30: From basic research to cancer therapy. Immunol Res 2013; 57(1-3): 151-8.
[42]
Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH,et al.Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory hodgkin lymphoma: An open-label Phase I trial. Clin Cancer Res 2017; 23(5): 1156-66.
[43]
Ao JY, Chai ZT, Zhang YY, Zhu XD, Kong LQ, Zhang N,et al.Robo1 promotes angiogenesis in hepatocellular carcinoma through the Rho family of guanosine triphosphatases signaling pathway. Tumour Biol 2015; 36(11): 8413-24.
[44]
Liang AB, Liu J, Sun Y,et al.Multi-target combined CAR (chimeric antigen receptor)-T cell preparation and preparation method. CN106822184 (2017).
[45]
Zhu FL, Liu XM. Transformation, multiplication culture and preservation method for T cell for expressing CD19 and CD20 antibody gene CAR (chimeric antigen receptor). CN106701827 (2017).
[46]
Zhou X. CAR-T cell preparation for treating breast cancer and preparation method thereof. CN105640990 (2016).
[47]
O’Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD,et al.A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med 2017; 9(399)
[48]
Ghoneim HE, Zamora AE, Thomas PG, Youngblood BA. Cell-intrinsic barriers of T cell-based immunotherapy. Trends Mol Med 2016; 22(12): 1000-11.
[49]
Boussiotis VA, Chatterjee P, Li L. Biochemical signaling of PD-1 on T cells and its functional implications. Cancer J 2014; 20(4): 265-71.
[50]
Serganova I, Moroz E, Cohen I, Moroz M, Mane M, Zurita J,et al.Enhancement of PSMA-directed CAR adoptive immunotherapy by PD-1/PD-L1 Blockade. Mol Ther Oncolytics 2017; 4: 41-54.
[51]
Hyun TL, Ju YL, Heejin L, Sang HL, Yu JM, Hyo JP,et al.Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab. Sci Rep 2017; 7(1): 5532.
[52]
Condomines M, Arnason J, Benjamin R, Gunset G, Plotkin J, Sadelain M. Tumor-targeted human T cells expressing CD28-based chimeric antigen receptors circumvent CTLA-4 inhibition. PLoS One 2015; 10(6): e0130518.
[53]
Shang XY, Zhang LL, Li G. Preparation of PD-1 knocked-outCD19 CAR (Chimeric Antigen Receptor)-T cell. CN107119021 (2017).
[54]
Rupp LJ, Schumann K, Roybal KT, Gate RE, Ye CJ, Lim WA,et al.CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep 2017; 7(1): 75-86.
[55]
Dai HJ, Li XL, Sun B, Zhang Z, Zhao XD, Xiong B. Method for knocking out PD-1 gene by utilizing CRISPR/Cas9technology to construct MSLN-targeted novel CAR-T cell and applicationof method. CN106480097 (2017)
[56]
Li HS. PD-1 CAR-T cell, preparation method therefor, andapplication thereof. WO2017177575 (2017)
[57]
Shi WX, Yang CX, Du Y, Fang YS. Anti-PD-L1-CAR-T,and preparation method and application thereof. CN106350533 (2016)
[58]
Xin BC. Application of CAR-T cell carrying PD-L1 and CTLA-4antibody genes in tumor immunology. CN105796597 (2017)
[59]
Suarez ER, Chang K, Sun J, Sui J, Freeman GJ, Signoretti S,et al.Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model. Oncotarget 2016; 7(23): 34341-55.
[60]
Qi W, Yu L, Kang LQ, Lin GW, Yu Z. OCTS-CAR doubletargetingchimeric antigen receptor, coding gene, recombinant expressionvector and establishment and application of OCTS-CARdouble-targeting chimeric antigen receptor, coding gene and recombinantexpression vector. CN107337736 (2017)
[61]
Qi W, Yu L, Kang LQ, Lin GW, Yu Z. OCTS technologybasedprostatic cancer CAR-T therapy vector and constructionmethod and application thereof. CN107164410 (2017)
[62]
Qi W, Yu L, Kang LQ, Lin GW, Yu Z. PSCA (prostate stemcell antigen) and PD-L1 targeted CAR based on OCTS (one CARwith two ScFvs)-CAR (chimeric antigen receptor), encoding geneand expression vector. CN107325185 (2017)
[63]
Qi W, Yu L, Kang LQ, Lin GW, Yu Z. OCTS (One CAR(Chimeric Antigen Receptor) with two ScFvs (Single-chain variableFragments)) technique based CAR-T (Chimeric Antigen Receptor-T cell immunotherapy) therapeutic vector for glioblastomaand construction method and application thereof CN107267555 (2017)
[64]
Qi W, Yu L, Kang LQ, Lin GW, Yu Z. Lymphoblastic leukemiaCAR-T (chimeric antigen receptor T cell immunotherapy)therapy carrier based on OCTS (One CAR with Two SeFvs) technologyas well as constructing method and application of lymphoblasticleukemia CAR-T therapy carrier CN107245500 (2017)
[65]
Qi W, Yu L, Kang LQ, Lin GW, Yu Z. Myeloid leukemiaCAR-T treatment carrier based on OCTS technology and constructionmethod and application of myeloid leukemia CAR-T treatmentcarrier. CN107177632 (2017)
[66]
Qi W, Yu L, Kang LQ, Lin GW, Yu Z. OCTS technology-based pancreatic cancer and malignant mesothelioma CAR-T therapy vector, as well as construction method and application thereof CN107299110 (2017).
[67]
Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 2015; 15(8): 486-99.
[68]
Long AH, Haso WM, Shern JF, Wanhainen KM, Murgai M, Ingaramo M,et al.4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med 2015; 21(6): 581-90.
[69]
Chang ZL, Chen YY. CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond. Trends Mol Med 2017; 23(5): 430-50.
[70]
Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med 2014; 65: 333-47.
[71]
Zhao YB, Shedlock D, June CH, Liu XJ. Enhanced antigenpresenting ability of RNA CAR T cells by co-introduction ofcostimulatory molecules. US2016340406 (2016)
[72]
Jensen MC, Riddell SR. Designing chimeric antigen receptors to effectively and safely target tumors. Curr Opin Immunol 2015; 33: 9-15.
[73]
Natsume A, Kuramitsu S, Ohno M. Uses of lenalidomide andCAR T-cells. WO2017176289 (2017)
[74]
Qi W, Yu Z, Kang LQ, Yu L. CAR-T cells with inhibitedsterol o-acyltransferase 1 (SOAT1) as well as preparation methodand application of CAR-T (Chimeric Antigen Receptor-T-cell Immunotherapy)cells. CN107058232 (2017)
[75]
Ichiyama K, Chen T, Wang X, Yan X, Kim BS, Tanaka S,et al.The methylcytosine dioxygenase Tet2 promotes DNA demethylation and activation of cytokine gene expression in T cells. Immunity 2015; 42(4): 613-26.
[76]
Motz G, Bushman FD, Fraietta JA,et al.CAR T cell therapies with enhancedefficacy. WO2017049166 (2017)
[77]
Sahin U, Reinhard K, Simon P, Mroz KA, Hobohm K. Enhancingthe effect of CAR-engineered T cells by means of nucleicacid vaccination. CA2985156 (2016)
[78]
Tamada K, Sakoda Y, Adachi K. CAR expression vector andcar-expressing t cells. PH12017500596 (2017)
[79]
Berdel W, Rossig C, Schliemann C, Altvater B, Kailayangiri S. Combination therapy comprising an inflammatory immunocytokineand a chimeric antigen receptor (CAR)-T cell. AU2017249694 (2017)
[80]
Shang XY. Preparation method of CD19 CAR-T cell secreting IL-12. CN106916789 (2017)
[81]
Sun XL, Li X. CAR-T cytotoxicity indicating vector.CN106086078 (2016)
[82]
Zhang QX, Wang H, Du X, Chen WH. TaqMan real-time fluorescent quantitative PCR kit for detecting peripheral blood CAR (Chimeric Antigen Receptor)-T cells. CN106399550 (2017)
[83]
Lu XA, He T, Ma L. Capture probe for detecting CAR-T cell,method for detecting cell content, and application. WO2017133222 (2017)
[84]
Liu DF. Quality of immunological synapse predicts effectivenessof chimeric antigen receptor (CAR) T cells. US2018231523 (2018)
[85]
Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I,et al.B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012; 119(12): 2709-20.
[86]
Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K,et al.Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6(224): 224-9.
[87]
Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M,et al.Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014; 124(2): 188-95.
[88]
Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: Recognition and management. Blood 2016; 127(26): 3321-30.
[89]
Wu LJ, Golubovskaya V, Lewis M, Zhou H. FLAG taggedCD19-CAR-T cells. WO2017172952 (2017)
[90]
Qi W, Kang LQ, Yu L, Xia RH. siRNA of humanized interleukin6, recombination expression carrier CAR-T and constructionmethod and application of recombination expression carrier CART.CN106636090 (2017)
[91]
Zhou X. CAR-T cell preparation for treating breast cancer andpreparation method thereof. CN105640990 (2016)
[92]
Zhang YD, Li XG, Xie HT. Preparation method of universalheterologous CAR-T cells and application. CN106591363 (2017)
[93]
He T, Lu XA, You YN, Hu XL. Universal type CAR-T cell,and preparation method and application thereof. CN106544321 (2017)
[94]
Dong J, Yang Y, Liu YZ, Xiong W, Cai M. Do you detect car T cell IFN paper ELISA kit of gamma release? CN205861688 (2017).
[95]
Dong J, Yang Y, Liu YZ, Xiong W, Cai M. Do you detectcar T cell IL 2 ELISA kit of release? CN205786667 (2016)
[96]
Low PS, Chu HY, Lee YGU. Methods and compositions forCAR T cell therapy. WO2017177149 (2017)
[97]
Anderson J, Fisher J, Pule M, Gustafsson K. T cell whichexpresses a gamma-delta T cell receptor (TCR) and a chimeric antigenreceptor (CAR). CA2982532 (2016)
[98]
Jiang S, Ji XL, Yun Z, Luo CX. Double chimeric antigenreceptor (CAR) modified T lymphocyte and preparation methodthereof. CN105087495 (2015)
[99]
Stassinopoulos A, Greenman WM. Compositions and methodsfor improved car-t cell therapies. US2017354724 (2017)
[100]
Choi K, Park H, Lee JE,et al.Chimeric antigen receptor to which anti-cotinine antibodyis linked, and use thereof. US2018256744 (2018)
[101]
Tan Y, Zhang HH. CD19-CAR-T cell carrying iCasp9 suicidegene and use thereof. CN107365798 (2017)
[102]
Qian QJ, Jin HJ, Li LF,et al.Molecular brake for rapidly stopping killing effectof CAR-T (T cell engineered with chimeric antigen receptors) andapplication of molecular brake. CN105330750 (2016)
[103]
Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR. Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. Blood 2012; 119(1): 72-82.
[104]
Zhang WF, Wu FL, Shao HW, Wang T, Huang XT, Li WL,et al.Chimeric adenoviral vector Ad5F35L containing the Ad5 natural long-shaft exhibits efficient gene transfer into human T lymphocytes. J Virol Methods 2013; 194(1-2): 52-9.
[105]
John LB, Chee TM, Gilham DE, Darcy PK. Genetic modification of mouse effector and helper T lymphocytes expressing a chimeric antigen receptor. Methods Mol Biol 2014; 1139: 177-87.
[106]
Sun XL, Li X, Xu H. Method for qualitatively detecting pollutionof VSVG sequence in CAR-T product. CN106086235 (2016)
[107]
Xiong B. Method for preparing CAR-T cell by CRISPR/Cas9.CN104894068 (2015)
[108]
Zhang C, Zhang Y, Liu XM, Zhang YL. Method for sitespecificintegration of CAR gene to AAVS1 site of T cell based ondouble-strand micro carrier. CN105524943 (2016)
[109]
Kelly K, Slukvin I. Method for treating a side effect of chimericantigen receptor (CAR) T cell therapy. WO2018184074 (2016)
[110]
Blazar B, Flynn RP, Pennell CA. Chimeric antigen receptor(CAR) T cells as therapeutic interventions for auto- and alloimmunity.US2018264038 (2018)
[111]
Wagner T, Scharenberg AM, Rawlings DJ, Sather B, Sahni J. Ccr5 disruption of cells expressing anti-hiv chimeric antigen receptor(CAR) derived from broadly neutralizing antibodies.US2017044240 (2017)
[112]
Zhang TC, Hu G, Gu CJ,et al.Recombinant gene construction of chimeric antigen receptor(CAR) for treating HIV (human immunodeficiency virus) infectionand application of chimeric antigen receptor. CN107098969 (2017)
[113]
Zhen A, Peterson CW, Carrillo MA, Reddy SS, Youn CS, Lam BB,et al.Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV / AIDS. PLoS Pathog 2017; 13(12): e1006753.
[114]
MacDonald KG, Hoeppli RE, Huang Q, Gillies J, Luciani DS, Orban PC,et al.Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest 2016; 126(4): 1413-24.
120
21
1
2